Shots: SpringWorks to receive $35M as upfront and $ 375M as clinical, regulatory, and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to […]readmore
Tags : Jazz Pharmaceutical
Profound Medical’s TULSA-PRO Receives the US FDA’s 510(k) Clearance for Ablation of Prostate Tissue Published: Aug 16, 2019 | Tags: 510(k), Ablation, Clearance, Profound Medical, Prostate Tissue, Receives, TULSA-PRO, The US […]readmore
Shots: Jazz acquires Cavion, in all stock transaction making total deal value $312.5M. Cavion to receive $52.5M up front, ~$260M milestones based on certain clinical, regulatory and commercial activities The […]readmore